CXCL8 and asthma: Unlike fluticasone propionate, the pan-JAK inhibitor LAS194046 showed similar efficacy inhibiting IL-8 and MMP9 release in neutrophils form healthy subjects and COPD patients and in a lesser extent in severe asthma.